0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Hyperuricemia Market Insight Epidemiology and Market Forecast 2028
Published Date: April 2019
|
Report Code: DELV-Mark-253
Home | Market Reports | Health | Pharmacy | Drugs & Medications
Hyperuricemia Market Insight Epidemiology and Market Forecast 2028

Hyperuricemia Market Insight Epidemiology and Market Forecast 2028

Code: DELV-Mark-253
Report
April 2019
100 Pages
Delveinsight
Region: Global,
Description
Table of Content
Tables & Figures

DelveInsight's "Hyperuricemia - Market Insight, Epidemiology and Market Forecast - 2028" report provides a detailed analysis of the Hyperuricemia epidemiology and market outlook for the 7MM.

Markets Covered
• United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2016-2028

Hyperuricemia Understanding and Treatment Algorithm
The market report provides the overview of the Hyperuricemia by providing the disease overview, definition, classification, symptoms, etiology, pathophysiology and diagnostic methods. It also covers the detailed treatment approaches and therapy areas under research and development for 7MM.

Hyperuricemia Epidemiology
The report provides a comprehensive account of the total patient pool, diagnosed cases and potential patient pool eligible for the treatment. It also includes the explanation of changing trends of epidemiology after evaluating numerous studies, survey reports and views of key opinion leaders. The Report provides the 10 years forecast from 2016 to 2028 segmented by seven major markets, enabling to understand the potential of the Hyperuricemia in the respective markets. The epidemiology data is presented with graphs and tables to provide a clear assessment of the landscape.

Hyperuricemia Product Profiles & Analysis
The drug chapter segment covers the complete analysis of marketed drugs and Phase III & late Phase II pipeline drugs. This division focuses on the recent breakthroughs like clinical development analysis, agreements and collaborations, clinical trial details, allotted designations, published results, pharmacological effects, patent expiry, and expected launch timings. Moreover, advantages and disadvantages of the therapy along with opinion of experts for marketed and emerging drugs are also provided.

Hyperuricemia Market Outlook
The report’s market outlook delivers an understanding of the country-specific revenue and share by analyzing the performance of the current therapies and potential uptake of new products. The in-depth analysis helps to recognize the growing demand of the market by evaluating the annual cost of therapy, compliance rate, competition with other therapies, covered patient segment, impact of emerging technology in the forecast period. The views from the key opinion leaders adds more value to the analysis. This segment provides the relevant graphs and tables to have an effective outline of the Hyperuricemia market.

Hyperuricemia Market Share by Therapies
This division provides an understanding of the rate of drug uptake, drugs including both recently launched and those which show potential to get launched during the forecast period from 2016-2028. The analysis is based on patient uptake by therapies, sales projection of each drug by studying the reasons behind the maximal use of new drugs. A comparative analysis is also done on the basis of market share and size by assessing the drugs uptake to project the drug positioning in the market.

Hyperuricemia Report Insights
• Patient Population in Hyperuricemia
• Therapeutic Approaches in Hyperuricemia
• Hyperuricemia Pipeline Analysis
• Hyperuricemia Market Size and Trends
• Hyperuricemia Market Opportunities
• Impact of upcoming Therapies in Hyperuricemia

Hyperuricemia Report Key Strengths
• 10 Year Forecast
• 7MM Coverage
• Epidemiology Segmentation
• Drugs Uptake
• Highly Analyzed Market
• Key Cross Competition

Hyperuricemia Report Assessment
• Current Treatment Practices in Hyperuricemia
• Unmet Needs in Hyperuricemia
• Market Attractiveness
• Market Drivers and Barriers

Key Benefits
• The report will help to develop Business Strategies by understanding the trends shaping and driving the Hyperuricemia market
• Organize sales and marketing efforts by identifying the best opportunities for Hyperuricemia market
• To understand the future market competition in the Hyperuricemia market.

1. Report Introduction
2. Hyperuricemia Market Overview at a Glance
2.1. Market Share Distribution of Hyperuricemia in 2016
2.2. Market Share Distribution of Hyperuricemia in 2028
3. Disease Background and Overview: Hyperuricemia
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Hyperuricemia in 7MM
4.3. Total Prevalent Patient Population of Hyperuricemia in 7MM – By Countries
5. Epidemiology of Hyperuricemia by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Hyperuricemia
5.1.3. Sub-Type Specific cases of the Hyperuricemia *
5.1.4. Sex- Specific Cases of the Hyperuricemia *
5.1.5. Diagnosed Cases of the Hyperuricemia
5.1.6. Treatable Cases of the Hyperuricemia
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Hyperuricemia
5.4.3. Sub-Type Specific cases of the Hyperuricemia *
5.4.4. Sex- Specific Cases of the Hyperuricemia *
5.4.5. Diagnosed Cases of the Hyperuricemia
5.4.6. Treatable Cases of the Hyperuricemia
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Hyperuricemia
5.5.3. Sub-Type Specific cases of the Hyperuricemia *
5.5.4. Sex- Specific Cases of the Hyperuricemia *
5.5.5. Diagnosed Cases of the Hyperuricemia
5.5.6. Treatable Cases of the Hyperuricemia
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Hyperuricemia
5.6.3. Sub-Type Specific cases of the Hyperuricemia *
5.6.4. Sex- Specific Cases of the Hyperuricemia *
5.6.5. Diagnosed Cases of the Hyperuricemia
5.6.6. Treatable Cases of the Hyperuricemia
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Hyperuricemia
5.7.3. Sub-Type Specific cases of the Hyperuricemia *
5.7.4. Sex- Specific Cases of the Hyperuricemia *
5.7.5. Diagnosed Cases of the Hyperuricemia
5.7.6. Treatable Cases of the Hyperuricemia
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Hyperuricemia
5.8.3. Sub-Type Specific cases of the Hyperuricemia *
5.8.4. Sex- Specific Cases of the Hyperuricemia *
5.8.5. Diagnosed Cases of the Hyperuricemia
5.8.6. Treatable Cases of the Hyperuricemia
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Hyperuricemia
5.9.3. Sub-Type Specific cases of the Hyperuricemia *
5.9.4. Sex- Specific Cases of the Hyperuricemia *
5.9.5. Diagnosed Cases of the Hyperuricemia
5.9.6. Treatable Cases of the Hyperuricemia
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Hyperuricemia
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Hyperuricemia
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Hyperuricemia : 7MM Market Analysis
12.1. 7MM Market Size of Hyperuricemia
12.2. 7MM Percentage Share of drugs marketed for Hyperuricemia
12.3. 7MM Market Sales of Hyperuricemia by Products
13. Hyperuricemia : Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Hyperuricemia in United States
13.1.2. Percentage Share of drugs marketed for Hyperuricemia in United States
13.1.3. Market Sales of Hyperuricemia by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Hyperuricemia in Germany
13.2.1.2. Percentage Share of drugs marketed for Hyperuricemia in Germany
13.2.1.3. Market Sales of Hyperuricemia by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Hyperuricemia in France
13.2.2.2. Percentage Share of drugs marketed for Hyperuricemia in France
13.2.2.3. Market Sales of Hyperuricemia by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Hyperuricemia in Italy
13.2.3.2. Percentage Share of drugs marketed for Hyperuricemia in Italy
13.2.3.3. Market Sales of Hyperuricemia by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Hyperuricemia in Spain
13.2.4.2. Percentage Share of drugs marketed for Hyperuricemia in Spain
13.2.4.3. Market Sales of Hyperuricemia by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Hyperuricemia in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Hyperuricemia in United Kingdom
13.2.5.3. Market Sales of Hyperuricemia by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Hyperuricemia in Japan
13.3.2. Percentage Share of drugs marketed for Hyperuricemia in Japan
13.3.3. Market Sales of Hyperuricemia by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

*Indication Specific

List of Tables

Table 1: Total Prevalent/Incident Cases of the Hyperuricemia in 7MM
Table 2: Total Prevalent/Incident Cases of the Hyperuricemia in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Hyperuricemia in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Hyperuricemia in United States (2016-2028)
Table 5: Sex- Specific Cases of the Hyperuricemia in United States (2016-2028)
Table 6: Diagnosed Cases of the Hyperuricemia in United States (2016-2028)
Table 7: Treatable Cases of the Hyperuricemia in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Hyperuricemia in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Hyperuricemia in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Hyperuricemia in Germany (2016-2028)
Table 11: Diagnosed Cases of the Hyperuricemia in Germany (2016-2028)
Table 12: Treatable Cases of the Hyperuricemia in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Hyperuricemia in France (2016-2028)
Table 14: Sub-Type Specific cases of the Hyperuricemia in France (2016-2028)
Table 15: Sex- Specific Cases of the Hyperuricemia in France (2016-2028)
Table 16: Diagnosed Cases of the Hyperuricemia in France (2016-2028)
Table 17: Treatable Cases of the Hyperuricemia in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Hyperuricemia in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Hyperuricemia in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Hyperuricemia in Italy (2016-2028)
Table 21: Diagnosed Cases of the Hyperuricemia in Italy (2016-2028)
Table 22: Treatable Cases of the Hyperuricemia in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Hyperuricemia in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Hyperuricemia in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Hyperuricemia in Spain (2016-2028)
Table 26: Diagnosed Cases of the Hyperuricemia in Spain (2016-2028)
Table 27: Treatable Cases of the Hyperuricemia in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Hyperuricemia in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Hyperuricemia in UK (2016-2028)
Table 30: Sex- Specific Cases of the Hyperuricemia in UK (2016-2028)
Table 31: Diagnosed Cases of the Hyperuricemia in UK (2016-2028)
Table 32: Treatable Cases of the Hyperuricemia in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Hyperuricemia in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Hyperuricemia in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Hyperuricemia in Japan (2016-2028)
Table 36: Diagnosed Cases of the Hyperuricemia in Japan (2016-2028)
Table 37: Treatable Cases of the Hyperuricemia in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Hyperuricemia in USD MM (2016-2028)
Table 42:7MM- Market Share Hyperuricemia by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Hyperuricemia by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Hyperuricemia in USD MM (2016-2028)
Table 45: United States-Market Share Hyperuricemia by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Hyperuricemia by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Hyperuricemia in USD MM (2016-2028)
Table 48: Germany-Market Share Hyperuricemia by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Hyperuricemia by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Hyperuricemia in USD MM (2016-2028)
Table 51: France-Market Share Hyperuricemia by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Hyperuricemia by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Hyperuricemia in USD MM (2016-2028)
Table 54: Italy-Market Share Hyperuricemia by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Hyperuricemia by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Hyperuricemia in USD MM (2016-2028)
Table 57: Spain-Market Share Hyperuricemia by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Hyperuricemia by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Hyperuricemia in USD MM (2016-2028)
Table 60:UK-Market Share Hyperuricemia by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Hyperuricemia by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Hyperuricemia in USD MM (2016-2028)
Table 63: Japan-Market Share Hyperuricemia by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Hyperuricemia by Therapies in USD MM (2016-2028)

List of Figures

Figure 1: Total Prevalent/Incident Cases of the Hyperuricemia in 7MM
Figure 2: Total Prevalent/Incident Cases of the Hyperuricemia in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Hyperuricemia in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Hyperuricemia in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Hyperuricemia in United States (2016-2028)
Figure 6: Diagnosed Cases of the Hyperuricemia in United States (2016-2028)
Figure 7: Treatable Cases of the Hyperuricemia in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Hyperuricemia in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Hyperuricemia in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Hyperuricemia in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Hyperuricemia in Germany (2016-2028)
Figure 12: Treatable Cases of the Hyperuricemia in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Hyperuricemia in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Hyperuricemia in France (2016-2028)
Figure 15: Sex- Specific Cases of the Hyperuricemia in France (2016-2028)
Figure 16: Diagnosed Cases of the Hyperuricemia in France (2016-2028)
Figure 17: Treatable Cases of the Hyperuricemia in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Hyperuricemia in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Hyperuricemia in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Hyperuricemia in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Hyperuricemia in Italy (2016-2028)
Figure 22: Treatable Cases of the Hyperuricemia in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Hyperuricemia in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Hyperuricemia in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Hyperuricemia in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Hyperuricemia in Spain (2016-2028)
Figure 27: Treatable Cases of the Hyperuricemia in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Hyperuricemia in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Hyperuricemia in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Hyperuricemia in UK (2016-2028)
Figure 31: Diagnosed Cases of the Hyperuricemia in UK (2016-2028)
Figure 32: Treatable Cases of the Hyperuricemia in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Hyperuricemia in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Hyperuricemia in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Hyperuricemia in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Hyperuricemia in Japan (2016-2028)
Figure 37: Treatable Cases of the Hyperuricemia in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Hyperuricemia in USD MM (2016-2028)
Figure 42:7MM- Market Share Hyperuricemia by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Hyperuricemia by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Hyperuricemia in USD MM (2016-2028)
Figure 45: United States-Market Share Hyperuricemia by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Hyperuricemia by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Hyperuricemia in USD MM (2016-2028)
Figure 48: Germany-Market Share Hyperuricemia by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Hyperuricemia by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Hyperuricemia in USD MM (2016-2028)
Figure 51: France-Market Share Hyperuricemia by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Hyperuricemia by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Hyperuricemia in USD MM (2016-2028)
Figure 54: Italy-Market Share Hyperuricemia by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Hyperuricemia by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Hyperuricemia in USD MM (2016-2028)
Figure 57: Spain-Market Share Hyperuricemia by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Hyperuricemia by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Hyperuricemia in USD MM (2016-2028)
Figure 60:UK-Market Share Hyperuricemia by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Hyperuricemia by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Hyperuricemia in USD MM (2016-2028)
Figure 63: Japan-Market Share Hyperuricemia by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Hyperuricemia by Therapies in USD MM (2016-2028)

SELECT A FORMAT
Added to Cart

Electronic (PDF)
$6250
This license allows only one user to access the PDF.

Electronic (PDF)
$12500
This license allows all the users of an enterprise residing in one location to access the PDF

Electronic (PDF)
$18750
This license allows all the employees of an enterprise to access the PDF.
Add to Cart
Buy Now (10% Discount)
OUR CUSTOMER
Strategic Venue Partners

RELATED REPORTS

Global and Japan Dasatinib Drugs Market Insights Forecast to 2027
Global and Japan Dasatinib Drugs Market Insights, Forecast to 2027

120 Pages
Type: Report
Code: QYRE-Auto-26C6576
Sun Sep 05 00:00:00 UTC 2021

Add to Cart

Global and Japan Methotrexate Oral Solution Market Insights Forecast to 2027
Global and Japan Methotrexate Oral Solution Market Insights, Forecast to 2027

120 Pages
Type: Report
Code: QYRE-Auto-15P6790
Sun Sep 05 00:00:00 UTC 2021

Add to Cart

Global and China Imatinib Mesylate Drugs Market Insights Forecast to 2027
Global and China Imatinib Mesylate Drugs Market Insights, Forecast to 2027

120 Pages
Type: Report
Code: QYRE-Auto-21K6705
Sun Sep 05 00:00:00 UTC 2021

Add to Cart

Global and Japan Inhalation Spray Based Drugs Market Insights Forecast to 2027
Global and Japan Inhalation Spray-Based Drugs Market Insights, Forecast to 2027

120 Pages
Type: Report
Code: QYRE-Auto-6R7008
Sun Sep 05 00:00:00 UTC 2021

Add to Cart